Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rna interference
3
×
alnylam pharmaceuticals
aminolevulinic acid
drugs
givosiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
biotech
boehringer ingelheim
deals
dicerna pharmaceuticals
eli lilly
fda
hepatitis b
indiana blog main
indiana top stories
johnson & johnson
national top stories
neurodegenerative diseases
onpattro
patisiran
paul matteis
primary hyperoxaluria
san francisco blog main
san francisco top stories
stifel financial
wisconsin blog main
wisconsin top stories
What
interference
3
×
rna
rnai
3
×
ago
alnylam
drug
medicine
pharmaceuticals
second
seek
speedy
abandoning
approval
baggage
cleared
companies
cuts
data
deal
development
dicerna
far
fda
free
gets
indicated
long
market
medicines
nasdaq
new
nod
ok
pharma
quick
signs
small
wasn’t
weeks
won’t
Language
Current search:
interference
×
rnai
×
" rna interference "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug